in this issue
Now's the time to find biomarkers on purpose
Treatment of cancer with oral drugs
Darwin, medicine and cancer
Communication skills training in oncology
Pharmacological management of gastrointestinal stromal tumours
A multicentre phase II gene expression profiling study of putative relationships between tumour biomarkers and clinical response with erlotinib in non-small-cell lung cancer
Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer
The strength of female sex as a prognostic factor in small-cell lung cancer
AIB1 is a predictive factor for tamoxifen response in premenopausal women
Adverse prognostic value of peritumoral vascular invasion
Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines
Daidzein induces MCF-7 breast cancer cell apoptosis via the mitochondrial pathway
North Central Cancer Treatment Group (NCCTG) N0432
An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
A randomized placebo-controlled study of tamoxifen after adjuvant chemotherapy in premenopausal women with early breast cancer (National Cancer Institute of Canada—Clinical Trials Group Trial, MA.12)
Treatment and survival in breast cancer in the Eastern Region of England
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy
Incidence, presenting features and outcome of extramedullary disease in multiple myeloma
The frequency, manifestations, and duration of prolonged cytopenias after first-line fludarabine combination chemotherapy
Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010
Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck
Malignant peritoneal mesothelioma
Health care-related predictors of husbands' preparedness for the death of a wife to cancer—a population-based follow-up
European Society for Medical Oncology (ESMO) Program for the Integration of Oncology and Palliative Care
A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies
Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
Phase I pharmacokinetic study of a weekly liposomal paclitaxel formulation (Genexol®-PM) in patients with solid tumors
Trends in cancer mortality in the elderly in Japan, 1970–2007
Postoperative nomogram for survival of patients with retroperitoneal sarcoma treated with curative intent
Post-imatinib surgery in advanced/metastatic GIST
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients
A prospective monitoring of fatal serious adverse events (SAEs) in a Dutch Colorectal Cancer Group (DCCG) phase III trial (CAIRO) in patients with advanced colorectal cancer
A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis
Taxanes for breast cancer during pregnancy
The role of an all-oral chemotherapy containing lomustine (CCNU) in advanced,fs progressive Hodgkin lymphoma
Second-line treatments of advanced non-small-cell lung cancer
Concomitant medications in cancer patients
Identifying optimal adjuvant treatment for individual patients
VEGFR TKI ‘resistance’ or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma
Irinotecan and mismatch repair deficiency
Potential role of everolimus in inducing cholestasis